Dr. Hemant K. Misra is Vice President of Clinical Development for Prolong Pharmaceuticals and is responsible for international clinical studies. He has over 30 years of experience in pharmaceutical and biopharmaceutical development, global clinical study management, and corporate development. Prior to joining Prolong, Dr. Misra managed the drug development, cGMP- manufacturing operations in US and abroad, CTM, quality systems, and multiple global clinical studies at XTL Biopharmaceuticals, Inc. (a public biopharmaceutical firm).
Dr. Misra has developed multiple antibodies and small molecules from Research and Development to various stages of clinical development, and some of them (HepeX-B®; DOS program) were licensed to other firms at advance stage of clinical development. He served in the management team and directed Product Development with ActiveCyte, Inc. MA, founded by The Boston Consulting Group, the leading strategy adviser to the global pharmaceutical industry. He managed a group of PhD and MD scientists to oversee and ensure the scientific rigor of ActiveCyte’s proprietary licensing opportunity search services for innovative clinical drugs and technology for R&D.
Prior to that, Dr. Misra was Director of Clinical Drug Development and Corporate Development at Genzyme Transgenics, a subsidiary of Genzyme Corporation, MA. He supervised global clinical drug development for six MAbs (e.g. Humira, Orencia, Tysabri) and therapeutic proteins (Atryn, IFNs, hGH, cytokines, ILs, tPA, PDGF- developed by transgenic goats) with major global biopharma companies worldwide. He also managed farm operations (transgenic goats) for different protein products and negotiated licensing opportunities.